Article Menu
-
Academic Editors
Oliver Waidmann
Fabian Finkelmeier
Vera Himmelsbach
- Subscribe SciFeed
- Recommended Articles
- Related Info Links
-
More by Authors Links
- on DOAJ
- Sho, T.
- Suda, G.
- Yamamoto, Y.
- Furuya, K.
- Baba, M.
- Ogawa, K.
- Kubo, A.
- Tokuchi, Y.
- Fu, Q.
- Yang, Z.
- Kimura, M.
- Kitagataya, T.
- Maehara, O.
- Ohnishi, S.
- Nakamura, A.
- Yamada, R.
- Ohara, M.
- Kawagishi, N.
- Natsuizaka, M.
- Nakai, M.
- Suzuki, K.
- Izumi, T.
- Meguro, T.
- Terashita, K.
- Takagi, T.
- Ito, J.
- Kobayashi, T.
- Miyagishima, T.
- Sakamoto, N.
- on Google Scholar
- Sho, T.
- Suda, G.
- Yamamoto, Y.
- Furuya, K.
- Baba, M.
- Ogawa, K.
- Kubo, A.
- Tokuchi, Y.
- Fu, Q.
- Yang, Z.
- Kimura, M.
- Kitagataya, T.
- Maehara, O.
- Ohnishi, S.
- Nakamura, A.
- Yamada, R.
- Ohara, M.
- Kawagishi, N.
- Natsuizaka, M.
- Nakai, M.
- Suzuki, K.
- Izumi, T.
- Meguro, T.
- Terashita, K.
- Takagi, T.
- Ito, J.
- Kobayashi, T.
- Miyagishima, T.
- Sakamoto, N.
- on PubMed
- Sho, T.
- Suda, G.
- Yamamoto, Y.
- Furuya, K.
- Baba, M.
- Ogawa, K.
- Kubo, A.
- Tokuchi, Y.
- Fu, Q.
- Yang, Z.
- Kimura, M.
- Kitagataya, T.
- Maehara, O.
- Ohnishi, S.
- Nakamura, A.
- Yamada, R.
- Ohara, M.
- Kawagishi, N.
- Natsuizaka, M.
- Nakai, M.
- Suzuki, K.
- Izumi, T.
- Meguro, T.
- Terashita, K.
- Takagi, T.
- Ito, J.
- Kobayashi, T.
- Miyagishima, T.
- Sakamoto, N.
Need Help?
Order Article Reprints
Journal: Cancers, 2022
Volume: 14
Number: 3938
3938
Article:
Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150
Authors:
by
Takuya Sho, Goki Suda, Yoshiya Yamamoto, Ken Furuya, Masaru Baba, Koji Ogawa, Akinori Kubo, Yoshimasa Tokuchi, Qingjie Fu, Zijian Yang, Megumi Kimura, Takashi Kitagataya, Osamu Maehara, Shunsuke Ohnishi, Akihisa Nakamura, Ren Yamada, Masatsugu Ohara, Naoki Kawagishi, Mitsuteru Natsuizaka, Masato Nakai, Kazuharu Suzuki, Takaaki Izumi, Takashi Meguro, Katsumi Terashita, Tomofumi Takagi, Jun Ito, Tomoe Kobayashi, Takuto Miyagishima and Naoya Sakamotoadd
Show full author list
remove
Hide full author list
Link:
https://www.mdpi.com/2072-6694/14/16/3938
MDPI offers high quality article reprints with convenient shipping to destinations worldwide. Each reprint features a 270 gsm bright white cover
and 105 gsm premium white paper, bound with two stitches for durability and printed in full color. The cover design is customized to your article
and designed to be complimentary to the journal.
Cite
Sho, T.; Suda, G.; Yamamoto, Y.; Furuya, K.; Baba, M.; Ogawa, K.; Kubo, A.; Tokuchi, Y.; Fu, Q.; Yang, Z.; et al. Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150. Cancers 2022, 14, 3938. https://doi.org/10.3390/cancers14163938
Sho T, Suda G, Yamamoto Y, Furuya K, Baba M, Ogawa K, Kubo A, Tokuchi Y, Fu Q, Yang Z, et al. Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150. Cancers. 2022; 14(16):3938. https://doi.org/10.3390/cancers14163938
Chicago/Turabian StyleSho, Takuya, Goki Suda, Yoshiya Yamamoto, Ken Furuya, Masaru Baba, Koji Ogawa, Akinori Kubo, Yoshimasa Tokuchi, Qingjie Fu, Zijian Yang, and et al. 2022. "Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150" Cancers 14, no. 16: 3938. https://doi.org/10.3390/cancers14163938
APA StyleSho, T., Suda, G., Yamamoto, Y., Furuya, K., Baba, M., Ogawa, K., Kubo, A., Tokuchi, Y., Fu, Q., Yang, Z., Kimura, M., Kitagataya, T., Maehara, O., Ohnishi, S., Nakamura, A., Yamada, R., Ohara, M., Kawagishi, N., Natsuizaka, M., ... Sakamoto, N. (2022). Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150. Cancers, 14(16), 3938. https://doi.org/10.3390/cancers14163938
